Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LE051 in Duchenne Muscular Dystrophy
NCT06900049Phase 1Recruiting
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Gene Editing, Gene Silencing, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LE051 in Duchenne muscular dystrophy (DMD), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Frequency of Adverse Events and Serious Adverse Events. Started Oct 2024; status: recruiting.
02
Drugs
LE051
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06900049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900049.